Resultados da pesquisa por Autor

1

MuTAR study, Phase II, open-label study of erlotinib (E) treatment in patients (pts) with locally advanced or metastatic non-small cell lung cancer (mNSCLC) who present activating mutations (MUT+) in the tyrosine kinase (TKI) domain of the epidermal growth factor receptor (EGFR), assessed the efficacy of 1L in Portuguese pts with mNSCLC EGFR Mut+

MuTAR study, Phase II, open-label study of erlotinib (E) treatment in patients (pts) with locally advanced or metastatic non-small cell lung cancer (mNSCLC) who present activating...

Por F. Barata, H. Queiroga, E. Teixeira, M.T. Almodovar, B. Parente, M. Soares
Publicado no Revista Portuguesa de Pneumología (2016)

Obter o texto integral

Artigo